Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. The
introduction of direct acting antiviral agents (DAAs) for its treatment represents a major …

More than 240 million people worldwide are chronically infected with hepatitis B virus (HBV).
Mother-to-child transmission remains the most important mechanism of infection in countries …

New drugs introduced to the market every year represent privileged structures for particular
biological targets. These new chemical entities (NCEs) provide insight into molecular …

In summary, DAAs have better tolerability and greater efficacy than interferon-based therapy
post-transplant. Drug–drug interactions must be carefully assessed when these newer …

Introduction: Hepatitis C virus (HCV) infection is a worldwide health problem, whose
management has been revolutionized after the availability of sofosbuvir, a direct-acting …

A new validated bioanalytical method based on LC tandem MS has been developed for the
simultaneous extraction and determination of sofosbuvir and ledipasvir in human plasma …

Hepatitis C virus (HCV) chronically infects about 2% of the world's population. Approximately
a quarter of these patients will develop, during their life, liver cirrhosis, which entails a high …

Hepatitis C virus (HCV) infection is a global health burden with an estimated 130–170
million chronically infected individuals and is the cause of serious liver diseases such as …

Introduction: Chronic hepatitis C virus (HCV) infection has recently become a curable
disease with antiviral therapy. The knowledge of drug interactions using direct-acting …

Hepatitis C is a chronic infection associated with considerable morbidity and mortality. In
recent years, there has been a shift in treatment paradigm with the discovery and approval of …